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Soft-tissue sarcoma (STS) is a histopathologically diverse group of tumors accounting for approximately 10,000 new malignancies
in the US each year. The proximal lower extremity is the most common site for STS, accounting for approximately one-third
of all cases. Coordinated multimodality management in the form of surgery and radiation is often critical to local control, limb
preservation, and functional outcome. Based on a review of currently available Medline literature and professional experience,
this paper provides an overview of the treatment of STS of the lower extremity with a particular focus on the modern role of
radiotherapy.
1.Introduction
Soft tissue sarcomas (STS) are a relatively rare, histopatho-
logically diverse group of neoplasms arising from mes-
enchymal cells including adipose, muscle, and connective
tissues. The natural history of STS typically involves growth
and compression of surrounding structures, rather than
direct invasion of surrounding tissues. The distant spread of
sarcoma is characteristically via early hematogenous spread,
most often to the lungs [1]. Lymphatic spread of sarcoma is
rare but may occur with certain histologic subtypes [2]. The
Centers for Disease Control (CDC) estimated that 10,660
new cases of STS would occur in 2009, with approximately
3,820 deaths as a result [3]. Estimates show a relatively
even distribution of STS between male and female patients,
with no apparent predilection for particular ethnicities or
races [3]. Despite a low overall incidence, STS is a fairly
common entity in radiation oncology clinics as level-one
evidence from several randomized controlled trials supports
a multidisciplinary approach [4–6].
Although STS can occur at any body site, the proximal
lowerextremity(orthigh)isthepredominantsiteand,there-
fore, forms the basis of this paper [1, 7]. Despite the array
of histological subtypes of STS, cases occurring in the lower
extremity are most commonly liposarcoma, undiﬀerentiated
pleomorphic sarcoma, tenosynovial sarcoma, ﬁbrosarcoma,
and epitheliod sarcoma.
2. Discussion
2.1. Anatomy. Enneking described the anatomy of the thigh
by separating it into 3 compartments—anterior, medial, and
posterior—with both oncologic and functional signiﬁcance
[8]. These distinctions have been widely used to describe
the anatomy of the thigh, especially as it relates to STS
[9]. The anterior compartment is particularly important
as it is the speciﬁc anatomic location of most proximal
lower-extremity tumors [10]. Its content includes the femur,
patella, quadriceps, sartorius, tensor fascia lata, and the
criticalneurovascularstructuresofthefemoralcanal.Includ-
ing the sartorious is debatable because it is set apart in
its own fascial envelope, some argue it is a compartment
unto itself [11, 12]. The medial compartment contains the
adductors, gracilis, pectineus, and neurovascular structures2 Sarcoma
Table 1: Selected outcomes for proximal lower-extremity soft tissue sarcoma.
Author Date
Number of
proximal lower
extremity tumors
Treatment type (%) Median follow
up (months)
Local
recurrences (%) Complications (rate)
Enneking et al.
[8]
University of
Florida
1981 40 Surgery alone 48 6 (15%) NR
Karakousis et al.
[13]
Roswell Park
1998 44
Compartment
resection—29 (66%)
Wide excision—15
(34%)
Radiotherapy—6 (14%)
49 6 (14%) NR
Yang et al. [4]
National Cancer
Institute
1998 73
Post-op RT—33 (45%)
Surgery alone—40
(55%)
115/118∗∗ 6 (13%)/5
(19%)∗∗ NR
Fabrizio et al.
[25]
Mayo Clinic
2000 15 Wide local excision
(100%) 55 0 (0%) NR
Vraa et al. [17]
Denmark 2001 152
Amputation (18%)
Wide local excision
(82%)
RT (21%)
52 14 (9%) NR
O’Sullivan et al.
[30]
Princess
Margaret
Hospital
2002 98 Pre-op RT (45%)
Post-op RT (55%) 39 NR
Wound complication:
Pre-op—20 (45%)
Post-op—15 (28%)
Virkus et al. [34]
University of
Florida
2002 130 Pre-op RT 71 10 (11%)∗ Wound complication:
41 (26%)∗
Rimner et al.
[10]
Memorial Sloan
Kettering
2009 255
Post-op RT
(BRT alone 63%, EBRT
alone 31%, both
modalities 6%)
71 24 (9%)
Wound
reoperation—24 (9%)
Edema—34 (13%)
Joint stiﬀness—32
(13%)
Nerve damage—20
(9%)
Fracture—15 (6%)
∗For all lower-extremity cases (both proximal and distal).
∗∗For high/lowgrade, respectively.
NR:not reported; RT:radiotherapy; EBRT:external-beam radiotherapy; BRT:Brachytherapy.
including the obturator artery and nerve and the profunda
femoris vessels. The posterior compartment contains the
semitendinosus, semimembranosus, biceps femoris, the pos-
terior portion of the adductor magnus muscles, and the
sciatic nerve [8].
2.2. Surgery. Surgical resection is a central component in
the management of STS, but the importance is magniﬁed
when considering disease of the proximal lower extremity
where most lesions are resectable. Historically, amputation
was the procedure of choice as it yields excellent local control
if adequate margins are obtained. Compartmental resection
is an alternative procedure that oﬀers good local control
and limb preservation but has been associated with high
morbidity and limited functional outcomes [13]. Current
surgical approaches to lower-extremity STS focus on limb
salvage and preserved functional status as a primary goal,
with amputation reserved for cases where tumor bulk or
presence of a vital surrounding structure prohibits satisfac-
tory oncologic margins [14].
To reduce the morbidity associated with amputation,
surgeons historically performed simple excisions of STS and
observed local recurrence rates of 60% to 90% [15]. Early
data on STS of the thigh from Enneking et al. showed
that local recurrence rates were signiﬁcantly lower when
moreradicalprocedureswereemployed(Table 1)[8].Several
studies looking at radical resection of STS at other extremity
sites have conﬁrmed Enneking’s work, with reported local
control rates ranging from 8% to 31%, suggesting that
margin status is a prime inﬂuence on local control [15, 16].Sarcoma 3
In one study examining patients with tumors of the proximal
lower extremity, Vraa and colleagues found that positive
surgical margins were associated with a signiﬁcantly higher
r a t eo fl o c a lr e c u r r e n c e ,b u tn o tw o r s es u r v i v a l[ 17].
In fact, data suggest that surgical margin status may be
the single most critical factor preventing local recurrence. In
aretrospectiveanalysis,Karakousisandcolleaguesfoundthat
local control with widely negative margins and surgery alone
was better than surgery plus adjuvant radiation for margins
less than 2cm [18]. These ﬁndings suggest that surgery alone
may be adequate, as long as margins are widely negative.
Several other investigators have reported local-control rates
approaching 90% in select patients treated by surgery alone
[19–23]. However, these small retrospective studies do not
use standardized patient selection criteria and are thus prone
to bias. A recent prospective trial by Pisters and colleagues
demonstrated that excellent local control and survival could
be achieved with surgery alone in patients with T1-stage
tumors of the extremities [24]. There is no surgical data
focusing speciﬁcally on the proximal lower extremity, but
Fabrizio et al. report local control and survival statistics
comparable to those from the adjuvant radiotherapy data in
aseriesofpatientsprimarilywiththightumors(44%)treated
withsurgeryalone(Table 1)[25].However,theScandinavian
data call into question this approach. In a retrospective
review including 469 cases of STS of the thigh, adding
radiotherapy to surgery improved local control irrespective
of surgical margin, grade, or depth [26].
In summary, the data suggest that wide excision alone
remains an option for well-selected patients with small
superﬁcial tumors. However, patients with STS of the
thigh commonly present with large subfascial tumors or
tumors abutting critical neurovascular structures, making
this strategy less practical.
2.3. Combined Modality. Although surgery alone is feasible
for carefully selected cases of STS of the proximal lower
extremity, the standard of care for treatment of primary
STS continues to be wide excision with radiotherapy before
or after surgery. Early evidence supporting the use of
radiotherapy in the treatment of STS came from retrospec-
tive data over 30 years ago [27, 28]. In the early 1980s,
a small randomized controlled trial (RCT) conducted at
the National Cancer Institute (NCI) compared amputation
to limb-sparing surgery and demonstrated low rates of
local recurrence following surgery plus radiotherapy and
equivalent rates of disease-free survival and overall survival
when compared to amputation [6]. This trial established
limb preservation as a viable goal and the standard of care.
However, it was not until the late 1990s when two larger
RCTs comparing adjuvant radiotherapy to no radiotherapy
have published that the beneﬁt of radiotherapy in STS was
ﬁrmly established [4, 5]. The timing (i.e., preoperative or
postoperative) of radiotherapy and the modality of radiation
delivery (i.e., brachytherapy or external-beam radiotherapy)
remain areas of controversy (Table 1). Likewise, the use of
adjuvant or neoadjuvant chemotherapy in nonmetastatic
STS of the thigh is controversial and will be addressed later.
2.4. Preoperative Radiotherapy. Although postoperative
radiotherapy was employed in the treatment of STS
in the landmark RCTs, preoperative radiotherapy is an
attractive option for a number of reasons. On a general
radiobiological level, radiation is more eﬀective in a well-
vascularized oxygenated tissue bed. A more radiosensitive
preoperative environment theoretically allows for lower
doses and smaller ﬁeld sizes and is thought to lead to
better functional outcomes. These endpoints have been
addressed in several diﬀerent studies speciﬁcally on STS.
Nielsen and colleagues demonstrated that preoperative
radiotherapy for STS of the extremity yields smaller ﬁeld
sizes when compared to postoperative radiotherapy [29].
Likewise, preoperative radiotherapy safely and eﬀectively
allows a lower cumulative dose to the involved ﬁeld and
subsequently better functional outcomes when compared to
postoperative radiotherapy [30–33]. Other reports indicate
that preoperative radiotherapy may allow easier resection of
the primary tumor because the peripheral ﬁbrosis creates a
palpable tumor capsule that is more amenable to resection
without tumor violation [34].
Several analyses indicate that preoperative radiotherapy
for STS yields similarly low rates of local recurrence and
comparable survival statistics as postoperative irradiation
[35–38]. Some studies indicate that preoperative irradiation
yields better local control rates, especially with large tumors
[39, 40]. However, preoperative radiation has been repeat-
edly associated with signiﬁcant wound complications [35,
41–43]. Wound complications tend to be more common and
more severe when the primary tumor is located in the thigh
or elsewhere in the lower extremity [30, 34, 41, 44, 45]. One
notable study from the Canadian National Cancer Institute
comparing preoperative to postoperative radiation for STS is
illustrative:acutewoundcomplicationsinpatients irradiated
before surgery were nearly double than in the postoperative
group [30]. In this study, complications were deﬁned as
secondary operations or procedures for wound repair with
or without anesthesia, hospital admission for wound care,
or persistent deep packing of wounds. A subset analysis
demonstrates that wound-complication rates are higher
in the proximal lower extremity, where 45% of patients
treated preoperatively had wound complications. A large
retrospective analysis focused on STS of the lower extremity
from the MD Anderson Cancer Center (MDACC; Houston,
TX) supports this trend. In this analysis, which included 263
(64%) lesions in the thigh, preoperative radiotherapy was
associated with a 34% wound-complication rate compared
with 16% in the postoperative cohort [46]. Lastly, data from
the University of Florida, where neoadjuvant radiotherapy
has been the treatment of choice for 30 years, provide
interesting data relating to tumors of the proximal lower
extremity. In a retrospective analysis of 209 patients (130
thigh primaries), the wound complication rate was 22%,
with a signiﬁcantly higher percentage of complications
occurring in proximal lower extremity cases [34].
Wound complications are clearly important; they are
inconvenient, uncomfortable and often lead to poor short-
term functional outcomes [47, 48]. Additionally, wound
complications may incur greater costs on the healthcare4 Sarcoma
system by leading to further surgical intervention [46].
However, the subjective variable deﬁnition of a wound
complication is problematic when reviewing these data.
2.5. Postoperative Radiotherapy. In the 1990s, two large
randomized controlled trials established the utility of post-
operative radiotherapy for STS of the extremity. Both studies
found signiﬁcant decreases in local recurrence, but no
diﬀerence in other endpoints like overall survival or freedom
fromdistantdisease.Yangrandomized141patientstoreceive
adjuvant external-beam radiation or no radiation follow-
ing limb-sparing surgery and reported separate results for
patients with low- and high-grade tumors. Among the high
grade group, approximately half of the patients had a tumor
located in the proximal lower extremity. At median follow up
of 9.3 years, local recurrence was 24% for patients receiving
no radiation and zero percent for patients receiving adjuvant
radiotherapy. Among the low-grade group, the majority of
patients again had a tumor located in the proximal lower
extremity. At median follow up of 9.9 years, local recurrence
was 33% for patients receiving no radiation, compared
with 0% for patients who received radiotherapy. These
diﬀerences in local recurrence were statistically signiﬁcant.
Although tumors of the proximal lower extremity ultimately
developed the most local recurrences, the authors did not
evaluate whether location itself was statistically signiﬁcant,
presumablyduetothelownumberofoverallrecurrences[4].
Pisters et al. randomized 164 patients to receive either
brachytherapy or no brachytherapy following resection of
STS of the extremity or trunk. After median follow up of
76 months, local control was signiﬁcantly improved in the
brachytherapy arm, while freedom from distant recurrence
and overall survival remained equal between groups. The
most speciﬁc anatomic descriptor is proximal extremity in
120 patients (73%), with no stratiﬁcation between upper
or lower extremity. On multivariate analysis, location of
the tumor in a proximal extremity was not associated with
a higher risk of local recurrence [5]. Like preoperative
external-beam radiotherapy, postoperative brachytherapy
has also been associated with high complication rates.
Researchersfromthesamegroupreportedthatifbrachyther-
apy catheters are loaded within 5 days postoperatively, the
wound complication rates approached 50% [49]. However,
with a modiﬁed technique of loading catheters later in
the postoperative period, wound complication rates for the
entiregroupdroppedtolessthan15%andwereequalinboth
arms [49, 50].
Though postoperative external-beam radiation has a
lower incidence of wound complications, data suggest that
these patients experience a higher degree of morbidity from
late radiation eﬀects. This likely represents sequelae of larger
ﬁeld sizes and higher doses used in the devascularized
p o s t s u r g i c a lt i s s u e .Al a r g er e t r o s p e c t i v es t u d yf r o mM D
Anderson suggests that postoperative irradiation is asso-
ciated with more long-term morbidity than preoperative
radiotherapy [37]. Randomized prospective data from a
CanadianNCItrialconﬁrmthisﬁnding.Inthistrial,patients
who received postoperative radiotherapy tended to have
more ﬁbrosis, edema, and joint stiﬀness; however, the results
are not statistically signiﬁcant [48]. These endpoints are
important: patients who experience ﬁbrosis, edema, or joint
stiﬀness as a result of treatment have signiﬁcantly greater
disability and impairment as measured by several validated
instruments[48].However,theseverityofdisabilityresulting
from radiation at any time in extremity sarcoma is debatable.
Concurrent quality of life and performance evaluations in
patients undergoing postoperative radiation have shown no
diﬀerence from patients not treated with radiation [4]. It is
important to note that although decreasing the dose or ﬁeld
size might be a worthwhile tactic to minimize the late eﬀects
of radiation, a review of 64 patients from the University of
Chicago found that smaller ﬁeld sizes signiﬁcantly decreased
local control [51]. Furthermore, evidence suggests that
patients treated to a total dose less than 62.5Gy have sig-
niﬁcantly poorer survival compared to patients treated to a
higher dose [52]. Little data are available speciﬁcally address-
ing dose or ﬁeld size in proximal lower-extremity tumors.
One study is available detailing the experience of post-
operative radiotherapy in the proximal lower extremity.
Investigators at Memorial Sloan Kettering Cancer Center
reviewed data for 255 patients treated with wide local
excision and postoperative radiotherapy and found a 9%
local recurrence rate. Local recurrence, distant metastasis-
free survival, and overall survival did not diﬀer signiﬁcantly
based on the anatomic compartment of tumor origin [10].
Interestingly, in this series of patients only with thigh
primaries, tumor size and margin status were not associated
with local recurrence, contrary to prior reports.
Although less widespread, published data suggest that
adjuvant brachytherapy is comparable to other techniques
in terms of local control, distant metastasis-free survival,
overallsurvival,andcomplications[5,53].However,recently
presented retrospective data from Memorial Sloan-Kettering
Cancer Center, where brachytherapy had been the stan-
dard of care, suggest that patients treated with external
beam intensity-modulated radiation therapy (IMRT) had
improved local control when compared to the brachytherapy
cohort, despite having more negative prognostic indicators
[54]. Further evaluation in the prospective setting would be
useful.
2.6. Radiotherapy Alone. Although adjuvant radiotherapy
has proven its eﬃcacy, deﬁnitive treatment of proximal
lower-extremity STS is rarely performed since nearly all
t u m o r sa r er e s e c t a b l ew i t hm o d e r nl i m b - s a l v a g ep r o c e d u r e s
or amputation. However, in select cases, patients who may
be medically inoperable or otherwise resistant to radical
surgery have been treated by radiation alone. Use of this
technique is limited; early reports of photon radiotherapy
alone for STS yielded poor results. Notably, some of this
subset of STS patients treated with radiation alone have had
poor overall health and performance status. Such factors
confoundsurvivalstatisticsmorethanlocalcontrolstatistics,
and, therefore, overall survival is diﬃcult to interpret. In the
1980s, Tepper and Suit reviewed 51 patients (including 14
thigh cases) with localized disease who had unresected or
partially resected STS and were managed with radiotherapy
alone for gross disease. At 5 years, local control wasSarcoma 5
only 33%, with poorer overall survival [55]. An updated
report from the same institution containing 112 patients
(20 thigh cases) demonstrates improved local control of
45% with more modern technology [56]. In view of poor
local control with conventional techniques, some centers
have employed fast-neutron therapy instead of conventional
photon therapy to deﬁnitively manage STS. Multicenter
European data encompassing over 1,100 patients shows local
control approximating 50% for patients treated deﬁnitively
or adjuvantly after an R2 resection with fast-neutron therapy
[57]. In the US, the University of Washington routinely
employs fast neutrons for unresectable or gross residual STS
and institutional analyses report 60% to 70% local control
rates[58,59].NeithertheEuropeannortheWashingtondata
mention results speciﬁc to the proximal lower extremity. In
sum, radiotherapy alone is infrequently used for STS of the
proximal lower extremity and data are scarce; however, data
extrapolated from other sites suggest that local control is
poorbutmaybeimprovedthroughdoseescalationorheavy-
ion therapy like neutrons.
2.7. Reirradiation. Combined-modality treatment for STS
of the proximal lower extremity yields local-control rates
close to 90%; local recurrences are rare but may have a
profound impact. Local recurrence is associated with poorer
overall survival and distant metastasis-free survival although
the mechanism of this association is unclear. Managing
recurrences remains a challenge to the surgeon and radiation
therapist.Recurrencescanbemanagedbywidelocalexcision
alone or in combination with radiation delivered as external
beam, brachytherapy, or both. No data speciﬁcally focusing
on reirradiation of the proximal lower extremity exist, and
many authors do not report tumor location or perform
subgroup analyses because the number of locally recurrent
patients reviewed is often quite low.
Historically, patients undergoing reirradiation of recur-
rent STS have poor local control, with 5-year actuarial con-
trol rates ranging from 30% to 70% [60]. More recent data
suggest that the local control for reirradiation may be worse.
Sixpatientswithproximallower-extremitytumorshavebeen
reirradiated at the University of Florida (Gainesville) from
1965 to 2007. Of these six patients, 3 patients experienced
severe complications, 2 of which required amputation. The
3 proximal lower-extremity patients who did not experience
severe complications from treatment died of metastatic
disease at an average of 1.5 years from retreatment. Recent
data from MDACC question the role of radiotherapy in
the management of recurrent disease. In a series of 62
patients with recurrent STS of various sites, local control was
not signiﬁcantly improved by adding radiotherapy to wide
local excision. Furthermore, the addition of radiotherapy
for locally recurrent STS substantially increased the rate of
complications, including amputation. The data are striking;
80% of irradiated patients experienced complications neces-
sitating medical or surgical interventions, compared to only
17% of patients managed by surgery alone [61]. Although
it is diﬃcult to extrapolate data for the proximal lower
extremity, all-site STS data clearly indicate that local control
is poor following a local recurrence and reirradiation must
be approached with caution.
2.8. Complications. As with any site, multimodality treat-
ment of proximal lower-extremity STS is prone to numerous
treatment-related complications, including wound infec-
tions, persistent edema, joint stiﬀness, nerve damage, and
femoral fracture (Table 1). As previously discussed, preop-
erative radiotherapy is associated with higher rates of acute
wound complications, while postoperative therapy is linked
to a higher risk for late complications.
A femoral fracture is a potentially major complication
following combined-modality treatment for STS of the
proximal lower extremity, with incidence rates ranging from
5% to 8.6% [10, 62–64]. Other analyses including additional
lower-extremity tumor sites ﬁnd a lower overall incidence
of fracture, but close inspection of the data reveals that
thigh primaries account for most fractures [46, 62]. A
femoral fracture is particularly devastating; up to two-thirds
of patients never achieve bone union and those who do often
require more than 1 year [65]. Numerous factors seem to
be associated with fracture risk, but periosteal stripping at
time of resection appears to be the strongest, with some
studies reporting coincident fracture rates ranging from
20% to 30% at 5 years [10, 63, 64]. A large retrospective
s e r i e sf r o mM D A C Cr e p o r t e dl o w e rr a t e so ff r a c t u r eb u t
did not include an analysis of periosteal stripping due to
inadequacy of operative reports [46]. Contrary to evidence
suggesting that periosteal stripping leads to more fractures,
a large series including 239 cases of STS in the proximal
lower extremity found that periosteal stripping was not
necessarily associated with fracture. Rather, the analysis
suggests that radiotherapy timing may play a bigger role in
fracture risk, with postoperatively irradiated patients having
9 times the fracture risk [62]. Although the association is
clear, this high relative rate of fracture may be a secondary
eﬀect related to the higher bone doses and larger irradiated
volumes utilized in the postoperative setting [66]. Several
otherfactors,includingtheuseofanyexternal-beamtherapy,
radiation to the entire circumference of bone, female gender,
chemotherapy, marginal excision, and age greater than 50
years have also been associated with an increased risk
for fracture, and the risk seems to be compounded when
periosteal stripping is performed [10, 46, 62–64].
The anatomic subsite within the proximal lower extrem-
ity has also been found to correlate with risk for complica-
tions and is predictably related to critical anatomic struc-
tures located nearby (i.e., nerves, lymphatic vessels, etc.).
Wound complications appear to be lower in the anterior
compartment of the thigh when compared to the other com-
partments, while edema is more common with tumors of
the medial compartment (Figure 1)[ 10]. Nerve damage, on
the other hand, is most common in posterior-compartment
tumors, likely secondary to the presence of the sciatic nerve
[10]. The location of the tumor in the anterior compartment
of the thigh has been associated with an increased risk of
fracture—with some reports suggesting 15 times the relative
risk—but this is uncertain as other investigators did not ﬁnd
a statistically signiﬁcant increase in relative risk [10, 62–64].6 Sarcoma
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Figure 1: Axial (a) and coronal (b) magnetic resonance imaging scans of soft tissue sarcoma arising from the adductor muscle and invading
the periosteum of the femur.
The relationship between anatomic subsite and functional
outcome after therapy remains unclear, with some reports
suggesting greater morbidity for anterior compartment
tumors [13] and others suggesting worse outcomes for
tumors of the posterior compartment [9].
2.9. New Techniques and Therapies. Despite the numerous
factors correlating with complications in multimodal man-
agement of proximal lower-extremity STS, several authors
have noted that some of the more common indicators,
like tumor size and anatomic location, may simply be
surrogates for volume of irradiated tissue [46]. In an eﬀort to
reduce irradiated volumes of normal tissues, some radiation
oncologists have begun to use IMRT techniques on the
thigh with the hope of reducing complications like femoral
fractures or tissue ﬁbrosis. In a review of 10 patients with
STS of the thigh, Hong et al. demonstrated that IMRT
provided better conformal target coverage and decreased
the exposure of surrounding normal tissues to high-dose
radiation when compared to three-dimensional conformal
radiotherapy(3D-CRT)plans.IMRTplansloweredtheV100
ofthefemurbyan averageof 57%, whichwouldtheoretically
reduce the risk for femoral fracture. Likewise, the V100 of
surrounding normal soft tissues in the treated thigh were
reduced by an average of 78% [67]. Despite advantages with
high-dose distribution, IMRT increases the integral dose
to normal tissue, particularly in the low- to intermediate-
dose range. This may result in a relative increased risk
of second malignancy and, if an adequate “strip” of the
normal lymphatic drainage is not spared, an increased risk
of lymphedema.
Fast-neutron therapy has been used in the US and
abroad, especially as previously described in the setting of
deﬁnitive treatment or following incomplete resections [57–
59]. Neutrons have several radiobiological characteristics
that increase their utility in the treatment of sarcomas, which
are frequently large rapidly growing tumors with necrotic
elements. Neutrons maintain eﬀectiveness in hypoxic envi-
ronments and throughout longer periods of the cell cycle
[58]. Despite the encouraging data in favor of fast-neutron
therapy, the percentage of late eﬀects remains high [59].
However, no studies have been performed looking speciﬁ-
cally at the utility of neutron therapy in extremity sites.
Like IMRT, proton therapy is recognized by US cooper-
ative groups as a viable option to improve the therapeutic
ratio of radiation for STS in adults [68] and children
[69] .F a v o r a b l eo u t c o m e sw i t hp r o t o nt h e r a p yh a v eb e e n
published for sarcomas of the head and neck, skull base,
and spinal cord [70]. Due to the cost and limited access
to facilities, proton therapy has not been routinely used in
the management of STS of the proximal lower extremity,
but in select cases it may be advantageous as it oﬀers theSarcoma 7
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Figure 2: Comparison of preoperative proton (a) and photon (b) dosimetry for soft tissue sarcoma of the thigh shown in Figure 1.T h e
tumor target volume is outlined in yellow and the anus is outlined in aqua blue. Note how the proton plan spares the perineal region and
lymphatic drainage of uninvolved soft tissue.
conformality of IMRT with the minimal integral tissue dose
of 3D-CRT (Figure 2). The radiobiologic characteristics of
protons are more similar to photons than neutrons and,
therefore,thereisadiminishedconcernregardinglateeﬀects.
2.10.Chemotherapy. Inspiteofthenumerousstudiesexplor-
ing its use, the role of chemotherapy has not been ﬁrmly
established for the treatment of STS. Furthermore, no data
speciﬁcally focusing on outcomes for patients with primary
tumors of the proximal lower extremity are available. The
Sarcoma Meta-analysis Collaboration (SMAC) pooled all-
site data from 14 RCTs and found improved local and distant
control, but no improvement in overall survival [71]. A
subgroup analysis suggested a signiﬁcant overall survival
beneﬁt for patients with extremity STS; however, other
investigations fail to show this correlation [72, 73]. In sum,
despitethevolumeofdata,theuseofadjuvantchemotherapy
in STS is debatable and guidelines suggest an individualized
approach for patients at highest risk [68]. Moreover, with
conﬂicting published data, few conclusions can be made
regardingtherelativeeﬀectivenessofadjuvantchemotherapy
when considering the thigh.
Due in part to the conﬂicting data on the eﬃcacy of
adjuvant chemotherapy and the need for improved systemic
disease control, some investigators have attempted aggressive
neoadjuvant chemotherapy—often combined with neoadju-
vant radiotherapy—to improve rates of resectability, recur-
rence, and survival. Although no study of neoadjuvant
chemotherapy has focused on the proximal lower extremity,
DeLaney and colleagues treated 48 patients with large
(>8cm) extremity tumors (70% proximal lower extremity)
with neoadjuvant chemoradiation and found a survival
advantage when compared to matched controls [74]. Despite
the suggested survival beneﬁt, toxicities were profound with
this regimen [75]. To summarize, although no randomized
trials have been performed to clarify the use of neoadjuvant
chemotherapy for lower-extremity STS, guidelines suggest
that neoadjuvant chemotherapy or chemoradiation are
acceptable treatments when lesions are potentially resectable
or when there is a concern for adverse surgical outcomes but
encourage their use as part of a clinical trial [68].
3. Conclusion
The proximal lower extremity is the most common site for
STS and surgery alone is not ideal for tumors with high-
risk features. Coordinated multimodality local therapy in
the form of surgery and radiation is often critical to local
control, limb preservation, and functional outcome in these
patients. Preoperative radiation may provide a functional8 Sarcoma
beneﬁt in long-term survivors without compromising local
control.Inselectcircumstances,adjuvantchemotherapymay
augment local management. Technical advances in surgery
and radiotherapy hold promise both in the primary setting
and in managing the diﬃcult scenarios of reirradiation and
unresectable tumors.
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